Aspen Appears Unfazed As Potential Difficulties Loom
Management Delivered A Defiant Results Call While The Street Remains Skeptical
Analysts posted wary notes about the prospects of South African pharmaceutical firm Aspen as its financial year came to an end, while management maintained confidence in the firm’s “solid results.”
You may also be interested in...
Companies and organizations that signed the contracts deny any heavy-handedness, with Johnson & Johnson saying it worked closely with South Africa on vaccine supply, and the vaccine alliance Gavi noting that the COVAX Facility provided the country with more than nine million doses free of charge.
Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.
BioFactura has completed a successful Phase I trial of its Stelara (ustekinumab) biosimilar BFI-751, which is expected to file in developed markets in 2026.